This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.